Abstract: Objective: To investigate the efficacy and safety of the Aspirin of antiplatelet aggregation combined with low-molecular-weight Heparin(LMWH) of anticoagulation therapy in acute cerebral infarction.Methods: Ninety-five patients with acute cerebral infarction were randomly divided into the control group(45 cases) and observation group(50 cases).The control group were treated with 100 mg of Aspirin by oral once a day,and the observation group were subcutaneously injected with 5 000 U of LMWH twice a day for 5 days based on the control group.The NIH Stroke Scale(NIHSS) score,Barthel Index(BI) and coagulation function between before and after treatment in two groups were compared,the progress rate of cerebral infarction and incidence of hemorrhage between two groups after treatment were compared.Results: The differences of the scores of NIHSS and BI before treatment between two groups were not statistically significant(P>0.05).Compared before treatment,the scores of NIHSS and BI in two groups significantly decreased and increased after 14 days of treatment,respectively(P<0.01),and the decreasing degree of NIHSS score and increasing degree of BI score in observation group were better than those in control group(P<0.01).The difference of the total effective rate between two groups was not statistically significant(P>0.05).The progress rate of cerebral infarction in observation group(6.0%) was lower than that in control group(22.2%)(P<0.05).The difference of the indicator of blood coagulation function between two groups before treatment was not statistically significant(P>0.05),but which was statistically significant after treatment(P<0.01).The difference of the total incidence rate of adverse reactions between two groups was not statistically significant(P>0.05).Conclusions: The treatment of acute cerebral infarction with the Aspirin of antiplatelet aggregation combined with low-molecular-weight Heparin of anticoagulation is safe and effective,which is worthy of clinical application.